AC Immune SA: Business Model, SWOT Analysis, and Competitors 2026

AC Immune SA stands as a leading company in Healthcare. Generating $4.37 million in annual revenue (growing -96.3% year-over-year) and carrying a market capitalization of $274.64 million, the company has cemented its position as a foundational player in the global Biotechnology landscape. Under the leadership of its leadership team, AC Immune SA continues to execute on a multi-year strategic vision that balances growth investment with shareholder returns.

This in-depth analysis examines AC Immune SA's business model, financial performance, competitive positioning, and SWOT analysis as of 2026. Whether you're evaluating AC Immune SA as an investment, benchmarking it against peers, or researching its strategy, this guide covers the key factors that define AC Immune SA's position in the Biotechnology market today.

What You Will Learn

1. How AC Immune SA generates revenue across its key business segments and the unit economics behind each
2. A data-backed SWOT analysis covering AC Immune SA's competitive strengths, operational weaknesses, market opportunities, and external threats
3. Who AC Immune SA's main competitors are and how the company compares on key financial metrics
4. AC Immune SA's key financial metrics: revenue, profit margins, market cap, free cash flow, and valuation multiples
5. AC Immune SA's strategic direction and what to watch in 2026-2027

Key Takeaways

• Revenue: $4.37 million annual revenue (TTM), +-96.3% YoY
• Market Cap: $274.64 million — one of the largest companies in the Healthcare sector
• Profitability: Gross margin 0.0%, operating margin -1671.9%, net margin 0.0%
• Free Cash Flow: $-18.47 million
• Return on Equity: -74.6% — reflects current investment phase
• Employees: 133 worldwide

Who Owns AC Immune SA?

AC Immune SA is publicly traded on the NASDAQ under the ticker symbol ACIU. As a public company, it is owned by millions of shareholders ranging from retail investors to major institutional holders.

The largest shareholders of AC Immune SA are typically major institutional investors including The Vanguard Group, BlackRock, and State Street Corporation — which collectively often hold 15-25% of publicly traded US companies. Insider ownership and the concentration of voting rights vary; investors should review the latest proxy statement filed with the SEC for precise ownership data.

AC Immune SA has approximately 101 million shares outstanding, with float shares of 0 million — the freely tradeable portion. The stock trades at $2.73 per share as of early 2026.

AC Immune SA's Mission Statement

AC Immune SA's strategic mission is aligned with its core business activities in the Biotechnology sector. The company's stated values and mission inform its capital allocation decisions, talent strategy, and long-term product roadmap. Mission statements for public companies are disclosed in annual reports and investor presentations — AC Immune SA's most recent proxy statement and annual report are the authoritative sources for its current mission and values.

A company's mission statement matters because it signals strategic intent to employees, investors, and customers. For AC Immune SA, the mission encompasses not just what the company does, but why it exists and how it creates value for stakeholders. Companies that maintain alignment between their stated mission and actual capital allocation decisions tend to build stronger brand trust and employee engagement over time.

In practice, AC Immune SA's strategic priorities as communicated to investors in 2025-2026 center on revenue growth and market share expansion, profitability improvement, and sustainable returns of capital to shareholders. These operational priorities translate directly into the business model and investment thesis discussed in the following sections.

How Does AC Immune SA Make Money?

As of 2026, AC Immune SA generates $4.37 million in annual revenue (growing -96.3% year-over-year), with a 0.0% gross margin and -1671.9% operating margin. Market capitalization stands at $274.64 million. Here is how the company generates its revenue:

As of 2026, AC Immune SA generates $4.37 million in annual revenue (growing -96.3% year-over-year), with a 0.0% gross margin and -1671.9% operating margin. Market capitalization stands at $274.64 million. Here is how the company generates its revenue:

Drug Discovery and Development

AC Immune SA primarily generates revenue through its drug discovery and development activities. The company focuses on discovering and developing innovative therapeutics for neurodegenerative diseases, particularly Alzheimer's disease and other protein misfolding disorders.

Collaboration and Licensing Agreements

AC Immune SA collaborates with pharmaceutical and biotechnology companies to advance its drug candidates. These collaborations often involve the licensing of AC Immune's proprietary technologies and intellectual property. The company receives upfront payments, milestone payments, and royalties from these partnerships, which contribute to its revenue stream.

One notable collaboration is the partnership with Genentech, a member of the Roche Group. AC Immune SA has entered into multiple agreements with Genentech to develop and commercialize therapeutic candidates, including anti-tau antibodies. These collaborations provide AC Immune with financial support and access to Genentech's extensive resources and expertise.

Research Funding

AC Immune SA also secures research funding from various sources, including government grants, foundations, and non-profit organizations. These funds enable the company to conduct preclinical and clinical research, supporting the advancement of its drug candidates. Additionally, AC Immune actively seeks collaborations with research institutions and academia to access additional research funding and expertise.

Diagnostics and Biomarker Services

In addition to drug discovery and development, AC Immune SA generates revenue through its diagnostics and biomarker services. The company leverages its expertise in protein misfolding diseases to develop and commercialize innovative diagnostic tools and biomarkers.

Tau PET Imaging Agents

AC Immune SA has developed tau positron emission tomography (PET) imaging agents that allow for the visualization and quantification of tau protein aggregates in the brain. These imaging agents are essential for the detection and monitoring of Alzheimer's disease and other tauopathies. AC Immune licenses these imaging agents to pharmaceutical companies for use in clinical trials, generating

In 2026, management's strategic priorities center on operational efficiency, market share expansion, and disciplined capital allocation. Investors should review AC Immune SA's latest annual report and quarterly earnings releases for the most current financial disclosures and strategic updates.

AC Immune SA Business Model Canvas

The Business Model Canvas framework provides a structured view of how AC Immune SA creates, delivers, and captures value.

Key Partners: AC Immune SA's key partners include suppliers, distributors, technology providers, and strategic alliances that enable its core operations. In the Biotechnology sector, these relationships provide supply chain resilience, expanded distribution, and access to complementary capabilities.

Key Activities: AC Immune SA's most important activities center on product development and innovation, sales and marketing, supply chain management, customer service, and regulatory compliance. The company's ability to execute these activities at scale is a core competency.

Key Resources: AC Immune SA's critical resources include its brand equity, intellectual property portfolio, customer relationships, human capital (133 employees), proprietary technology, and financial resources ($108.47M in cash).

Value Propositions: AC Immune SA delivers value to customers through product quality, brand trust, convenience, innovation, and price competitiveness. The specific value proposition varies by customer segment but consistently addresses core needs in the Biotechnology market.

Customer Relationships: AC Immune SA maintains customer relationships through multiple channels including direct sales teams, digital platforms, customer service centers, and loyalty/membership programs. Customer retention is a key operational priority.

Channels: AC Immune SA reaches customers through its own direct channels (stores, website, apps), third-party retailers and distributors, and partner networks. The mix of direct vs. indirect channels affects margin structure and customer data ownership.

Customer Segments: AC Immune SA serves multiple distinct customer segments, which may include consumers, small and medium businesses, enterprise clients, and government entities — depending on its product portfolio and market positioning.

Cost Structure: AC Immune SA's major costs include cost of goods sold (N/A of revenue), research & development, sales & marketing, general & administrative expenses, and capital expenditures. Total operating costs represent 1771.9% of revenue.

Revenue Streams: AC Immune SA generates revenue through its core product and service offerings.

AC Immune SA Competitors

AC Immune SA competes against Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Pfizer (PFE), AbbVie (ABBV), Eli Lilly (LLY) and others in the Biotechnology segment of the Healthcare sector.

AC Immune SA SWOT Analysis

A SWOT analysis examines AC Immune SA's internal strengths and weaknesses alongside external opportunities and threats.

Strengths

• Established Market Position: AC Immune SA holds an established position in the Biotechnology sector, with a track record of serving customers and generating value across its core business activities.
• Industry Expertise: The company's deep expertise in Biotechnology — developed over years of operation — provides meaningful barriers to entry and customer relationship advantages that newer competitors must overcome.

Weaknesses

• Revenue Decline: Year-over-year revenue declined 96.3%, raising questions about demand for AC Immune SA's core offerings and requiring management to articulate a credible recovery path.

Opportunities

• Total Addressable Market: AC Immune SA operates in the Biotechnology segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment translate to meaningful revenue upside, particularly as the company expands its product portfolio and geographic reach.
• International Expansion: Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for AC Immune SA's products and services.
• Strategic Acquisitions: With $108.47M in cash and strong free cash flow generation, AC Immune SA is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Threats

• Macroeconomic Sensitivity: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. AC Immune SA's revenue is not fully insulated from macroeconomic cycles, and a recession scenario could meaningfully impact demand.
• Regulatory and Geopolitical Risk: Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on AC Immune SA's business model across key markets.
• Talent Competition: Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly critical in an era of AI-driven competition.

Conclusion

AC Immune SA enters 2026 as a significant player in the Biotechnology market, with a strategy focused on sustainable growth and competitive positioning in a rapidly evolving sector.

The primary opportunities ahead lie in expanding market share, operational efficiency improvements, and selective geographic expansion. The key risks to monitor include competitive pressure from established peers and new entrants, macroeconomic headwinds, and regulatory developments in AC Immune SA's core markets.

For investors and analysts, AC Immune SA represents an important company to understand within the Healthcare sector. Key metrics to track include revenue growth, margin trends, and competitive positioning updates.

Data Sources

Financial data and business information for this analysis was sourced from: Yahoo Finance – AC Immune SA, SEC EDGAR – AC Immune SA Filings, and AC Immune SA's investor relations materials.

All financial figures reflect the most recent publicly available disclosures. Investors should verify current data before making investment decisions.

Frequently Asked Questions

1. What does AC Immune SA do?

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are desi

2. How much revenue does AC Immune SA make?

AC Immune SA generated $4.37 million in annual revenue (TTM), with -96.3% year-over-year growth.

3. What is AC Immune SA's market cap?

AC Immune SA's market capitalization is approximately $274.64 million as of early 2026.

4. Is AC Immune SA profitable?

AC Immune SA has faced profitability challenges recently. Investors should review the latest quarterly earnings reports.

5. Who are AC Immune SA's competitors?

AC Immune SA competes in the Biotechnology sector against companies including Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Pfizer (PFE).

6. Does AC Immune SA pay dividends?

AC Immune SA does not currently pay a dividend, choosing to reinvest earnings into growth initiatives.

7. What is AC Immune SA's stock ticker?

AC Immune SA trades on the NASDAQ under the ticker symbol ACIU.

8. What is AC Immune SA's P/E ratio?

Valuation multiples for AC Immune SA can be found on major financial platforms such as Yahoo Finance, Bloomberg Terminal, or the company's latest annual report filing.

9. How many employees does AC Immune SA have?

AC Immune SA employs approximately 133 people worldwide as of the most recent disclosure.

10. What is AC Immune SA's competitive advantage?

AC Immune SA's competitive advantages include its established brand, scale in Biotechnology, and track record of execution in the Healthcare sector.